Sernova Biotherapeutics Inc (SVA.TO)
- Previous Close
0.2000 - Open
0.1950 - Bid 0.1900 x --
- Ask 0.2000 x --
- Day's Range
0.1950 - 0.1950 - 52 Week Range
0.1500 - 0.4000 - Volume
68,600 - Avg. Volume
138,575 - Market Cap (intraday)
64.055M - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date Mar 17, 2025 - Mar 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.50
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. The comoany was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is headquartered in London, Canada.
www.sernova.comRecent News: SVA.TO
View MorePerformance Overview: SVA.TO
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SVA.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SVA.TO
View MoreValuation Measures
Market Cap
64.05M
Enterprise Value
63.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-152.63%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.14M
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
1.21M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.11M